Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,147
- Phase 21,063
- Phase 1819
- Phase 1/Phase 2442
- Phase 3425
- Phase 4238
- Phase 2/Phase 396
Top conditions
- Multiple Sclerosis343
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis140
- Type 1 Diabetes133
- Atopic Dermatitis129
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Type 1 Diabetes Mellitus63
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)73
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals60
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California491
- Maryland195
- Alabama175
- Florida144
- Arizona142
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT07290309Recruiting
Remote exercise program for cancer survivors
This study tests a remote guided exercise program for cancer survivors to see if it helps with recovery and well-being. It is designed for people who have finished their main cancer treatments and are not already exercising a lot.
Fort Collins, ColoradoAges 18 years+ - NCT07292792Recruiting
PrEP support through peer health navigation for people leaving jail
This study tests whether adding a peer health navigator (someone with lived experience who helps with health) to regular re-entry services can help more people learn about and start PrEP, a medicine that prevents HIV.
Dallas, TexasAges 18–99 - NCT07292480Recruiting
Monthly NfL monitoring for relapsing-remitting MS
This trial tests whether monthly blood tests for a nerve protein (NfL) can detect hidden disease activity in people with relapsing-remitting multiple sclerosis (RRMS) who are on certain first-line treatments. It aims to find out if this monitoring helps catch early signs of active disease before symptoms appear.
NiceAges 18–55 - NCT07292558Recruiting
Support program for young adults with type 1 diabetes
This study looks at whether a special program designed for emerging adults (ages 16-19) with type 1 diabetes can help improve blood sugar control and overall health. It takes place in the Seattle area and involves both the program and usual diabetes care.
Seattle, WashingtonAges 16–19 - NCT07292805Recruiting
Bronchial thermoplasty for severe asthma
This study tests a procedure called bronchial thermoplasty for adults with severe asthma that is not controlled with standard treatments. It aims to see if this can help reduce asthma attacks in people who have already tried or cannot use biologic therapies.
AmsterdamAges 18 years+ - NCT07293364Recruiting
Study of C1-inhibitor test for hereditary angioedema diagnosis
This study checks if a blood test measuring C1-inhibitor function can help diagnose hereditary angioedema (HAE), a rare condition that causes painful swelling episodes. If you or a close family member have had swelling without rash or itching that lasts 1-5 days and doesn't get better with allergy meds, this trial may be for you.
AlgiersAges 12 years+ - NCT07293715RecruitingPhase 4
Comparing glucose management during labor in type 1 diabetes
This trial looks at two ways to manage blood sugar levels during labor in pregnant people with type 1 diabetes. It aims to find the safest approach for both the patient and the baby.
Columbus, OhioAges 18 years+ - NCT07294365RecruitingPhase 2
Study of DZD8586 for adults with chronic ITP
This study tests an investigational drug called DZD8586 for people with long-term ITP (low platelets) that hasn't improved with standard treatments. The goal is to see if it can safely raise platelet counts and reduce bleeding risk.
Jinan, ShandongAges 18 years+ - NCT07294625RecruitingEarly Phase 1
Gene therapy for relapsed/refractory multiple myeloma
This trial tests a new gene therapy, LVIVO-TaVec200, for people with multiple myeloma that has returned or not responded to other treatments. The goal is to see if it can help control the cancer.
Zhengzhou, HenanAges 18 years+ - NCT07294677RecruitingPhase 1/Phase 2
Study of capivasertib, venetoclax, and low-intensity chemo for ALL/LBL
This trial tests a combination of targeted drugs (capivasertib and venetoclax) with a gentle form of chemotherapy for adults with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) that has come back or has not responded to previous treatment. The goal is to see if this approach is safe and effective.
Chicago, IllinoisAges 18 years+ - NCT07295808Recruiting
Study of IgA antibodies in kidney disease
This study looks at a specific type of antibody called IgA in patients with certain kidney diseases. It aims to understand which IgA antibodies cause kidney damage, which could help develop better treatments.
LimogesAges 18 years+ - NCT07296276Recruiting
Testing the CareSens Air 3 glucose monitor in type 1 diabetes
This study tests how accurate a new continuous glucose monitor (CGM) called CareSens Air 3 is for adults with type 1 diabetes. You would wear the sensor on your skin to track blood sugar levels, and it may help you manage your diabetes more easily.
Escondido, CaliforniaAges 18–65 - NCT07297329RecruitingPhase 3
Newly diagnosed multiple myeloma trial for transplant-ineligible patients
This trial tests a new drug called SCTC21C combined with standard treatments (bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see if this combination is safe and works better than current options.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07297602RecruitingPhase 2
Oral roflumilast for moderate to severe eczema in teens and adults
This study tests an oral medicine called roflumilast to see if it helps treat moderate to severe eczema in people aged 12 and up who haven't used other systemic treatments recently. It's a pilot study to check both safety and how well it works.
Al Mansurah, Dakahlia GovernorateAges 12 years+ - NCT07297563RecruitingPhase 2
Anti-CD38 antibody vs rituximab for hard-to-treat ITP
This trial tests a new antibody drug (anti-CD38) compared to a standard drug (rituximab) for adults with ITP that hasn't responded well to steroids. The goal is to see if the new drug works better at raising platelet counts and reducing bleeding risk.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07298785Recruiting
HIV prevention study led by peers for women
This study tests a peer-led approach to HIV prevention for women. It looks at whether having a peer (someone like you) help choose and use prevention tools can work better than standard care.
KampalaAges 15 years+ - NCT07299149RecruitingPhase 2
Testing a new triple-drug combination for untreated follicular lymphoma
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
Tianjin, Tianjin MunicipalityAges 18–90 - NCT07299422RecruitingPhase 2
Study of SHR-2173 for people with lupus
This trial tests a new drug called SHR-2173 for people with active lupus. It aims to see if it can reduce disease activity when taken with standard treatments.
Beijing, Beijing MunicipalityAges 18–65 - NCT07299500Recruiting
Toxoplasmosis study in non-HIV immune compromised patients
This study looks at toxoplasmosis infections in people with weakened immune systems (not caused by HIV). It aims to learn more about how these infections happen and how they affect patients.
StrasbourgAges 18 years+ - NCT07300514RecruitingPhase 3
Golidocitinib vs placebo for T-cell lymphoma maintenance
This trial tests if taking golidocitinib pills after first treatment helps keep peripheral T-cell lymphoma from coming back. You'll either get the study drug or a placebo (no active drug), and your doctor will watch how you do.
ShanghaiAges 18 years+ - NCT07300683RecruitingPhase 1
Modified immune cells for T-cell leukemia/lymphoma
This trial tests a new type of immunotherapy called anti-CCR9 CAR T cells for people whose T-cell leukemia or lymphoma has not responded to standard chemotherapy. The treatment uses your own immune cells that are modified in a lab to find and attack cancer cells that have a specific marker (CCR9) on their surface.
LondonAges Any age - NCT07301060Recruiting
Smartphone app and sensor study for teens with asthma
This study tests if using a special sensor with your inhaler and a smartphone app can help teens with asthma feel better. If you have daily asthma symptoms or use your rescue inhaler often, this study might be for you.
Jacksonville, FloridaAges 13–17 - NCT07301736RecruitingPhase 2
New asthma inhaler study for mild to moderate asthma
This trial tests whether a new inhaler (CHF5993) works as well as the current standard for adults with mild to moderate asthma. It compares how well the medicine controls asthma and opens airways.
Buenos AiresAges 18–75 - NCT07301892Recruiting
AI help for rheumatoid arthritis diagnosis
This trial tests whether artificial intelligence (AI) can improve how doctors spot complications in people newly diagnosed with rheumatoid arthritis (RA), a condition that causes joint pain and swelling. The goal is to see if AI can make diagnosis faster and more accurate in real-world hospital settings.
Beijing, Beijing MunicipalityAges Any age
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,763 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.